Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial)

BACKGROUND: Patients with cystic fibrosis (CF) are at risk for early bone loss, and demonstrate increased risks for vertebral fractures and kyphosis. A multicenter, randomized, controlled trial was conducted to assess the efficacy, tolerability, and safety of therapy with oral alendronate (FOSAMAX;...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Chest
Main Authors: Papaioannou, Alexandra, Kennedy, Courtney C., Freitag, Andreas, Ioannidis, George, O’Neill, John, Webber, Colin, Pui, Margaret, Berthiaume, Yves, Rabin, Harvey R., Paterson, Nigel, Jeanneret, Alphonse, Matouk, Elias, Villeneuve, Josee, Nixon, Madeline, Adachi, Jonathan D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5104558/
https://ncbi.nlm.nih.gov/pubmed/18641106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1378/chest.08-0608
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados